動脈血栓症とは動脈上に発生する血餅であり、脈拍欠損、筋痛、筋痙攣、皮膚蒼白、冷感といった症状があります。血餅の発生場所により、脳卒中、心臓発作、末梢動脈疾患（PAD）など、さまざまな重篤な症状を引き起こします。喫煙や肥満、糖尿病、高血圧、高コレステロールなどが素因となる要素であり、血栓溶解薬や手術といった治療法があります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Arterial Thrombosis - Overview
Arterial Thrombosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arterial Thrombosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arterial Thrombosis - Companies Involved in Therapeutics Development
Anthos Therapeutics Inc
Astellas Pharma Inc
GLSynthesis Inc
Jiangsu Hengrui Medicine Co Ltd
MDI Therapeutics Inc
Oasis Pharmaceuticals LLC
Protheragen Inc
Suzhou Ribo Life Sciences Co Ltd
Arterial Thrombosis - Drug Profiles
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
ASP-6537 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GLS-409 - Drug Profile
Product Description
Mechanism Of Action
GPR-310 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MDI-2517 - Drug Profile
Product Description
Mechanism Of Action
History of Events
OA-150 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
S-007867 - Drug Profile
Product Description
Mechanism Of Action
SHR-2004 - Drug Profile
Product Description
Mechanism Of Action
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit NMMHC IIA for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
SR-060 - Drug Profile
Product Description
Mechanism Of Action
Arterial Thrombosis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Arterial Thrombosis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Arterial Thrombosis - Pipeline by Anthos Therapeutics Inc, 2022
Arterial Thrombosis - Pipeline by Astellas Pharma Inc, 2022
Arterial Thrombosis - Pipeline by GLSynthesis Inc, 2022
Arterial Thrombosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Arterial Thrombosis - Pipeline by MDI Therapeutics Inc, 2022
Arterial Thrombosis - Pipeline by Oasis Pharmaceuticals LLC, 2022
Arterial Thrombosis - Pipeline by Protheragen Inc, 2022
Arterial Thrombosis - Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Arterial Thrombosis - Dormant Projects, 2022
Arterial Thrombosis - Dormant Projects, 2022 (Contd..1)
List of Figures
Number of Products under Development for Arterial Thrombosis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
